Zenas Yiu

PhD opportunity @ UoM

Multi-omics analysis for treatment response in #psoriasis #PsA using national datasets

Competitive studentship through MRC-DTP scheme

Supervised by James Bluett, Magnus Rattray, Ali Al-Janabi, and myself

Deadline 8th Nov

www.findaphd.com/phd...

PhD opportunity @ UoM - long-term outcomes and use of antibiotics in #hidradenitis using the CPRD

Competitive studentship funded by the MRC-DTP scheme

Supervised by myself, Darren Ashcroft, Stevie Shoop-Worrall, and Tjeerd Van Staa

Deadline 8th Nov

www.findaphd.com/phd...

Another bivalent biologic presented at #EADV2025, this time for #atopicdermatitis #eczema - IL-13 and IL17A/F inhibitor Galvokimig in a small phase IIA RCT

potentially very helpful for Asian Th17 AD phenotype or patients at risk of phenotypic switch

The third study presented at #EADV2025 from Novartis using spatial transcriptomics to look at #hidradenitis

Some beautiful pictures showing the distribution of fibroblasts, B cells, plasma cells, T cells around a lesion

IMO more data to suggest a need to hit multiple targets

Exciting to hear a new bivalent drug that targets TNF and OX40L Brivekimig for the treatment of #hidradenitis - we likely need more drugs that have multiple targets to treat this difficult disease

Looking forward to the explanatory phase III RCTs

#EADV2025

Probably the closest effort to precision medicine so far in dermatology presented by Michel Gillet - using nanostring measuring gene expression - to differentiate between skin diseases outside of morphology

#EADV2025

Good and slower burning response from OX-40 inhibitor rocatinlimab for #atopicdermatitis - results from the phase III RCT ROCKET-SHUTTLE which allows concomitant topical steroids

#EADV2025

Really interesting new mechanism of action to target T-regulatory cells in #atopicdermatitis for Rezpeg

seems safe and effective in this phase 2b RCT but again this choice of as observed open label extension arm makes it difficult to interpret longer term effect

#EADV2025

Izokibep shows moderate response, again around 13% delta mark for HiSCR75 at week 12, for #hidradenitis

Not convinced more single target biologics are what we need

#EADV2025

Good to see phase III data for povorcitinib for #hidradenitis. Delta for primary endpoint of HiSCR50 slightly disappointing around 10-12%, but good to see draining tunnels resolving better.

Why use as observed imputation for extension, which is biased?

#EADV2025

Do antibiotics have a direct anti-inflammatory activity in #hidradenitis? Some data to show they do, especially clindamycin, from a 3D seboskin model study from Germany

#EADV2025

Two interesting spatial transcriptomics studies in #hidradenitis highlighting abnormal epithelialisation and the complex immunological pathogenesis respectively in the EHSF session

#EADV2025

Great to hear the new classification for epidermal differentiation disorders from Edel O’Toole, which follows a logical naming convention starting with the gene.

#EADV2025

Delighted to have given a plenary on stories of drug discoveries and research in dermatology in my home town of Hong Kong! Thank you to Chester Lai and the GCDS committee for your kind invitation.

#GCDS2025 #RxEpi

Great to hear from Henry Lim in the 1st plenary of the Global Chinese Dermatology Summit that ustekinumab and adalimumab are part of the WHO list of essential medicines!

#GCDS2025 #psoriasis

We have a great #PhD opportunity with a multi-disciplinary supervisory team to understand the impact of UV radiation on #eczema #atopicdermatitis using methods from epidemiology, wearables, data science, and behavioural science

Deadline 7/7/2025!

www.findaphd.com/phd...

Target emulation trial w/ data from British Dermatologists Biologics & Immunomodulators Register, studied 231 PSO Rx w/ MTX + Adalimumab against 1553 PSO on ADA. @1Yr MTX did not augment ADA only responses based on Rx survival (79% vs 78%) or PASI75 (49% vs 52%). jamanetwork.com/journals/jam...

Interested in making a difference for people with #psoriasis in the UK?

Apply for this @PsoriasisUK funded PhD with me, Binh Phan, Richard Warren, and Gabriel Rogers and use data from @BADBIR and trials to conduct cost-effectiveness analyses

www.findaphd.com/phd...

would be very interested to hear about real-world experience with JAKi for SJS/TEN!

Honoured to present on evidence based care in #psoriasis alongside amazing speakers for alopecia areata, urticaria, CTCL, acne, and photoaging at the #AAD2025 yesterday.

Learnt a lot from all the speakers on the topics at hand as well as how to get complex messages across

Much needed study on new therapies in bullous pemphigoid - more sustained remission for dupilumab after corticosteroid taper

#AAD2025

Slow and steady response for rocatinlimab, OX40 receptor inhibitor for atopic dermatitis

Looks like it is quite targeted and safe in this phase III study - but if the thought is a slower response they probably needed to have a later primary outcome timepoint

#AAD2025

Nice to see new therapies coming through for cutaneous lupus erythematosus - phase II data on deucravacitinib for CLE

#AAD2025

Icotrokinra showing high but slightly lower response rates compared to injectable IL23i for #psoriasis - nonetheless a very high effectiveness for an oral medication

#AAD2025

Much needed study to look at the impact of dupilumab on itch in epidermolysis bullosa and ichthyosis

need a bigger study with a control arm but very promising!

#AAD2025

ESK-001 showing promise as a targeted inhibitor of TYK2 for psoriasis in a phase II trial - now for the phase III study to confirm findings for blinded primary outcome

#AAD2025

Very high negative predictor values presented by Skin Analytics for their DERM AI device in ruling out melanoma

I think gold standard for this based on dermatologist diagnosis is still suboptimal and would like longer term data with follow up

#AAD2025

Nice early results from a small phase IIa trial on Bempikibart, IL7/TSLP inhibitor biologic for alopecia areata in the late breaking session by Brett King

Looks like it results in more durable responses compared to JAK inhibitors after treatment cessation

#AAD2025

Fascinating use of AI to increase access to patch testing for allergic contact dermatitis from the Mayo Clinic

#AAD2025

Second great debate on use of gene expression profiling tests for melanoma and SCC by Emily Chu and David Cotter

Definitely need a RCT to be able to say something about cost effectiveness - right population critical